84 results about "Mucoprotein" patented technology

The invention relates to the technical field of microorganisms, in particular to a culture medium and a method for culturing Ackermania muciniphila for activating Amuc-1260 by using lambda-carrageenan as a carbon source, according to the culture method, the lambda-carrageenan is used for replacing a traditional carbon source, thallus growth and proliferation can be remarkably promoted, the effect is optimal under the condition of 2.00 g / L, and the culture cost is low. Compared with the conventional carbon source (glucose), the carbon source is improved by 92.91%. Further research finds that the lambda-carrageenan can induce the Akk bacteria to up-regulate the expression of glycoside hydrolase such as Amuc-1260 and enhance the activity of pathways such as glycosaminoglycan degradation, amino acid metabolism and insulin signals, so that the metabolic adaptability and energy utilization efficiency of the bacteria are improved. Meanwhile, the Akk bacteria secrete more functional short-chain fatty acids such as acetic acid, propionic acid and the like under the condition, and have the effects of regulating intestinal health and maintaining metabolic homeostasis. The invention provides a new theoretical basis and technical support for large-scale culture of Akk bacteria and development of a metabiotic product.

Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.

The invention discloses a bionic cross-linked film-forming repair dressing containing mussel mucoprotein and a preparation method of the bionic cross-linked film-forming repair dressing, and relates to the technical field of medical instruments. The bionic crosslinking film-forming repair dressing containing the mussel mucoprotein is prepared from the following components in parts by weight: 30 to 40 parts of bionic crosslinking agent, 25 to 35 parts of humectant, 10 to 20 parts of natural high polymer material, 1 to 10 parts of mussel mucoprotein, 1000 parts of purified water and 5 to 15 parts of pH regulator. PEG-DOPA is formed through cross-linking, the DOPA content and stability are remarkably improved, the adhesion-repair-anti-inflammatory effect of mussels mainly depends on the dopa content, the effect of the dressing is remarkably enhanced through improvement of the DOPA content and stability, the dressing is more convenient to use through the flexibility change of a film, the dressing is more suitable for dynamic and wet wounds, and the application range of the dressing is widened. The medicine has a remarkable effect on chronic ulcer and burn.

The invention belongs to the technical field of biological medicine, and discloses ovomucoprotein glycopeptide and application thereof. According to the application of the ovomucoprotein glycopeptide in preparing the medicine for preventing or treating the alcohol-induced acute gastric mucosal lesion, the percentage of the gastric mucosal lesion area can be reduced to 1.0% or below when the ovomucoprotein glycopeptide is used for protection. The invention creatively discovers and verifies that the glycopeptide derived from ovomucin has a remarkable protective effect on acute gastric mucosal lesion induced by alcohol. According to the discovery of the application, the application field of the natural active ingredient ovomucin is definitely expanded to the protection of acute gastric mucosal lesion for the first time, the technical problem that efficient and natural gastric mucosal protection ingredients are lacked in the prior art is solved, and a brand-new material basis and a clear direction are provided for developing a novel gastric mucosal protective agent.

The invention belongs to the field of microorganisms and medicine health care, and relates to an ackermania muciniphila strain and application thereof, the preservation number of the ackermania muciniphila strain is CGMCC (China General Microbiological Culture Collection Center) No.34370, and a 16SrDNA (Deoxyribose Nucleic Acid) sequence of the ackermania muciniphila strain has 93% similarity with a sequence shown as SEQ ID NO: 1. The new ackermania muciniphila strain (AKKBC300) is separated from a healthy human body and has good safety; good tolerance to low pH value and bile salt is shown in vitro, and it is indicated that the compound can reach the intestinal tract through the upper digestive tract and play a role; according to the present invention, genomics analysis results prove that the bacterial strain contains the gene Akkermansia BC00573 with high homology with the known probiotic functional protein Amuc1100, such that the molecular basis is provided;

The invention relates to application of serum mucoid or Tax1 binding protein 1 in preparation of a medicine for treating medicine-induced liver injury or organ ischemia-reperfusion injury. Experiments prove that by using an adeno-associated virus (AAV) carrying an Orm2 gene, ORM2 recombinant protein or knocking down a TAX1BP1 gene, liver injury and liver failure, ischemia reperfusion injury of the liver, ischemia reperfusion injury of the kidney and ischemia reperfusion induction of intestines induced by APAP treatment can be effectively relieved, and the application has the advantages that the liver injury and liver failure, the ischemia reperfusion injury of the kidney and the ischemia reperfusion induction of the intestine can be effectively relieved; and a new target spot and a new treatment method are provided for treating the ferroptosis-related organ injury.

The present application relates to the field of microorganisms, in particular to a mucinophilic Akkermansia strain and application thereof, the mucinophilic Akkermansia has a preservation number of CCTCC NO: M 20241304.The mucinophilic Akkermansia AKK-86 of the present application has good effects of promoting iron absorption, improving iron metabolism, and relieving intestinal inflammation.In addition, the mucinophilic Akkermansia of the present application can also promote the production of GLP-1, and has potential application in reducing blood sugar and weight loss products.

The invention relates to the technical field of biological medicines, in particular to application of extracellular vesicles of Ackermann muciniphila in preparation of trichina control products. Experiments prove that by supplementing the AKK bacterium extracellular vesicles, the intestinal flora of a mouse can be remarkably improved, the immune balance of a host is regulated, and the pathological change of the intestinal tract of the mouse can be improved. Experimental results show that the AKK bacterium extracellular vesicles have a certain protection effect on trichina infected mice and have the advantages of being efficient, safe, easy to produce on a large scale and the like, and a brand new technical solution is provided for prevention and treatment of trichinosis.

The invention discloses a preparation method of Chinese yam mucin anti-drag hydrogel. The preparation method comprises the following steps: crushing Chinese yam blocks and deionized water to obtain a Chinese yam mucus mixture; centrifuging, standing and layering, extracting supernate, and filtering to obtain a plant extracting solution; purifying by adopting a reverse osmosis method, and air-drying to obtain Chinese yam mucoprotein; the preparation method comprises the following steps: adding gelatin into a PBS solution, heating and stirring, then adding N, N-dimethylformamide and methacrylic anhydride, heating and stirring, dialyzing, and freeze-drying to obtain a gelatin derivative grafted with carbon-carbon double bonds; the preparation method comprises the following steps: adding a gelatin derivative into deionized water, heating and stirring, adding Chinese yam mucoprotein, N, N '-methylene bisacrylamide and ammonium persulfate, stirring, centrifugally defoaming, and drying to obtain the Chinese yam mucoprotein drag-reducing hydrogel. According to the preparation method of the Chinese yam mucoprotein anti-drag hydrogel, Chinese yam mucoprotein macromolecular chains are connected into a network structure by using N, N '-methylene bisacrylamide molecules, so that water-soluble Chinese yam mucoprotein is prevented from being dissolved and lost in a water body, and long-term lubrication and anti-drag are realized.

The invention relates to an application of inactivated ackermania muciniphila Akk09 in preparation of a postbiotic preparation for controlling body weight and improving obesity. The preservation number of the ackermania muciniphila Akk09 is CCTCC (China Center For Type Culture Collection) NO: M 20242401. According to the present invention, the new use of the Ackermania muciniphila Akk09 is developed, the research basis is provided for the wide application of the Ackermania muciniphila Akk09, the brand new strategy for controlling body weight and improving obesity is developed, the inactivated Ackermania muciniphila Akk09 strain has significant effects on controlling body weight and improving obesity, and the inactivated Ackermania muciniphila Akk09 strain has significant application prospects. The Ackermania muciniphila Akk09 strain is a probiotic, the safety of the product is high, and the resistance is not easy to generate.

The application belongs to the technical field of microorganisms, and provides application of Propionibacterium freudenreichii subsp. shermanii in preparation of products for improving constipation and depression, wherein the Propionibacterium freudenreichii subsp. shermanii NHNK-616 is preserved in the China Center for Type Culture Collection on July 1, 2024, and the preservation number is CCTCC NO: M 20241429. The inventors find that NHNK-616 has the functions of promoting 5-HT secretion, up-regulating intestinal aquaporin and brain-derived neurotrophic factor genes, metabolically producing gamma-aminobutyric acid, inhibiting growth of Candida albicans, inhibiting hypha formation of Candida albicans, combining with hypha of Candida albicans, and up-regulating expression of intestinal defensin and mucin genes, and therefore can be used for preparing products for improving constipation and depression.

The present invention relates to a linker unit-cytotoxic small molecule drug, an antibody specifically binding to target mucoprotein 17 (MUC17), an antibody drug conjugate and uses thereof, and a composition and a detection system containing the antibody molecule, the linker unit-cytotoxic small molecule drug and the antibody drug conjugate.

This invention discloses a clean modification process for yam starch with high slow-digestible starch content, belonging to the field of clean starch modification technology. It aims to solve the problems of existing modification processes relying on exogenous additives, high costs, and difficulty in balancing starch digestibility and stability. This invention uses fresh yam as raw material and obtains a co-precipitation system retaining endogenous mucoprotein through isoelectric point sedimentation. Based on this, vacuum alternating pulsed steam treatment is used, utilizing pressure difference and thermal effects to promote the migration of endogenous proteins at the starch particle interface and construct a stable composite structure. Subsequently, annealing is performed under high humidity conditions to induce ordered rearrangement of molecular chains. This process, without adding exogenous substances, precisely controls the starch structure, significantly increases the slow-digestible starch content, and improves the processing stability of the product. It has advantages such as being green and clean, highly safe, and highly functional.

The present invention provides an isolated Akkermansia muciniphila, a composition containing same, and a use thereof, which can be used for treating, preventing, or alleviating obesity, metabolic disorders caused by obesity, diabetes, inflammation, liver and kidney disease, liver disease, cardiovascular and cerebrovascular diseases, tumors, etc.

The invention discloses mucoprotein nano-selenium gas motor hydrogel as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The preparation method of the mucoprotein nano-selenium gas motor hydrogel comprises the following steps: adding a carbonyl compound and selenite into an emulsifier solution, and adding a reducing agent for mixing reaction to obtain a nano-selenium gas motor, oxidized mucoprotein and the nano-selenium gas motor are mixed, then a cross-linking agent is added, the oxidized mucoprotein is subjected to a cross-linking reaction to form gel, and the mucoprotein nano-selenium gas motor hydrogel is obtained. The mucoprotein nano-selenium gas motor hydrogel is constructed by wrapping a gas motor into a mucoprotein hydrogel delivery system, the mucoprotein nano-selenium gas motor hydrogel can be specifically delivered to a colitis disease part through rectal administration, and meanwhile, the safe and controllable release and mucous membrane protection effects of the nano-selenium gas motor are realized; therefore, a new thought is provided for treating enteritis.

This invention discloses a method for studying the mechanism by which the mucoprotein channel 1 (TRPML1) regulates the outflow of zinc ions from lysosomes and induces changes in mitochondrial ATP. This method uses 13 nm AuNPs as loading materials to construct a logic-gated sensor for pH and zinc ion regulation within lysosomes and for TRPML1 mRNA in the cytoplasm. It also uses 5 nm AuNPs as loading materials to construct a sensor targeting mitochondrial ATP for cell imaging. This method enables the detection of mRNA and zinc ions in the cytoplasm, lysosomes, and mitochondria. 2+ ATP-associated ATP sensors, Zn 2+ Three sensors—a sensor, an mRNA sensor, and an X-ray sensor—are used simultaneously to image cells, aiming to answer questions about the mechanisms of ATP changes in mitochondria under the regulation of zinc ion efflux from lysosomes by TRPML1.

The invention discloses mucoprotein hydrogel loaded with cerium-dihydromyricetin nano-enzyme as well as a preparation method and application of the mucoprotein hydrogel, and relates to the technical field of biological medicines. The preparation method comprises the following steps: carrying out coordination reaction on dihydromyricetin and Ce < 4 + > to obtain cerium-dihydromyricetin nano-enzyme; the preparation method comprises the following steps: coupling hyaluronic acid with dopamine to obtain hyaluronic acid-dopamine; the preparation method comprises the following steps: coupling mucoprotein with aminophenylboronic acid to obtain mucoprotein-aminophenylboronic acid; the preparation method comprises the following steps: mixing cerium-dihydromyricetin nano-enzyme, hyaluronic acid-dopamine and mucoprotein-aminophenylboronic acid, and reacting, so as to obtain the mucoprotein hydrogel loaded with the cerium-dihydromyricetin nano-enzyme. The mucoprotein hydrogel loaded with the cerium-dihydromyricetin nano enzyme can be used for effectively treating ulcerative colitis and has an important clinical application value.

The application belongs to the technical field of microorganisms, and discloses a propionic acid-producing propionic acid bacteria NHNK-621 and application of the propionic acid bacteria in preparation of products for improving constipation and memory, the bacteria strain has been preserved in the China Center for Type Culture Collection on November 25, 2024, and the number is CCTCC NO: M 20242631. The propionic acid bacteria NHNK-621 provided by the application has the functions of promoting 5-HT secretion, up-regulating intestinal aquaporin and brain-derived neurotrophic factor genes, metabolically producing gamma-aminobutyric acid, inhibiting growth of Candida albicans, inhibiting hypha formation of Candida albicans, combining with hypha of Candida albicans, up-regulating intestinal defensin and mucin gene expression, in addition, the bacterial biofilm can increase the colonization ability to intestinal epithelial cells, and can be used for preparing products for improving constipation and memory.

The invention belongs to the technical field of biological medicines, and particularly relates to application of ackermania muciniphila and recombinant trichina serine protease carried by a derivative of the ackermania muciniphila to preparation of a medicine for treating intestinal inflammation symptoms. According to the present invention, the ackermann muciniphila and the ackermann muciniphila derivative carrying recombinant trichina serine are firstly disclosed, such that the physical barrier of the intestinal mucosa is repaired through the synergistic effect, the expression of TNF-alpha, IL-6, IL-1beta and other proinflammatory factors is specifically regulated and inhibited, the intestinal flora structure is remodeled, and the intestinal inflammation state is significantly improved; experimental results show that the Ackerman muciniphila and the derivative thereof carrying the recombinant trichina serine protease can significantly relieve weight loss of mice with intestinal inflammation induced by DSS, reduce DAI score, and reverse the phenomena of shortened colon and abnormal swelling of spleen. According to the invention, the probiotics and the parasite-derived protein are combined, so that the method has the advantages of high efficiency, safety and easiness in large-scale production, and a new biological preparation strategy is provided for accurate treatment of IBD.

The invention discloses application of leuconostoc mesenteroides subsp. Mesenteroides in improvement of constipation and depression, and belongs to the technical field of marine microorganisms. The invention discloses a leuconostoc mesenteroides subsp. Mesenteroides NHNK-613, which is preserved in the China Center for Type Culture Collection on July 1, 2024, and the preservation number of the leuconostoc mesenteroides subsp. Mesenteroides NHNK-613 is CCTCC (China Center for Type Culture Collection) NO: M 20241431. The NHNK-613 has the functions of promoting 5-HT secretion, up-regulating intestinal aquaporin and brain-derived neurotrophic factor genes, metabolizing to generate gamma-aminobutyric acid, inhibiting the growth of candida albicans, inhibiting the formation of candida albicans filaments, combining the candida albicans filaments and up-regulating intestinal defensin and mucoprotein gene expression; the traditional Chinese medicine composition can be used for preparing products for improving constipation and depression.

Provided are innovative compositions for tethering blocking an inactivating of airborne respiratory infectious viruses. The compositions comprise bispecific proteins with two different antigen binding regions (ABR), which are typically configured as immunoglobulin “single variable domains” (ISV). A first ISV binds to a surface protein found on an airborne infectious virus. A second ISV binds to a mucin protein, e.g. a mucin protein present on ocular, nasopharyngeal, tracheal and / or oral surfaces of a mammal. The two ISV are joined by a polypeptide linker.

The application provides a composition for promoting growth of Akkermansia and application, the composition comprises colostrum basic protein, beta-glucan and 2'-fucosyllactose, wherein, in the composition, the concentration ratio of the colostrum basic protein, beta-glucan and 2'-fucosyllactose is (0.025-0.3):(0.03-0.15):(0.6-2.5). The composition can fully meet the nutritional requirements of Akkermansia bacteria, especially mucinophilic Akkermansia bacteria, can effectively promote the growth of Akkermansia bacteria, can be used for culturing Akkermansia bacteria in vitro, and can promote the growth of mucinophilic Akkermansia bacteria in human intestinal tract, increase the potential probiotic Akkermansia bacteria in the intestinal tract, and improve intestinal health.

The invention discloses a Pickering emulsion adjuvant as well as a preparation method and application thereof, belongs to the technical field of immunology, and aims to solve the problems of safety and stability of a common emulsion in the prior art and the problems of mucous membrane residence and mucus penetration and capability of targeted activation of antigen presenting cells. The composition comprises an emulsifier, water, an antigen and an oil phase, the emulsifier is mucoprotein nanoparticles. The vaccine adjuvant is suitable for mucous membrane residence, and can achieve the effects of having excellent ion concentration characteristics, pH stability, temperature stability and storage stability, being capable of protecting the integrity of antigens, being capable of targeting antigen presenting cells, and being capable of residing at mucous membrane parts.

The invention relates to the technical field of biomedical detection, in particular to salivary glucose detection test paper which comprises a supporting mechanism, the supporting mechanism comprises a lower shell, an upper shell is connected to the top of the lower shell in an inserted mode, a sample adding hole is formed in the outer surface of the upper shell, an observation hole is formed in the outer surface of the end, away from the sample adding hole, of the upper shell, and the observation hole is communicated with the lower shell. The inner wall of the observation hole is fixedly connected with a transparent plate, a detection mechanism is arranged between the lower shell and the upper shell, the detection mechanism comprises a connecting shell, the connecting shell is clamped in the lower shell, the inner wall of the connecting shell is fixedly connected with a water absorption layer, the upper surface of the water absorption layer is fixedly connected with a reaction layer, and the upper surface of the reaction layer is fixedly connected with a water outlet. An adsorption layer is fixedly connected to the outer surface of the side, close to the sample adding hole, of the reaction layer, large-particle impurities in saliva are sequentially filtered through the filtering layer, the adsorption layer and the reaction layer, mucin and other interferents in the saliva are adsorbed, and therefore interference is eliminated, and the reliability of a detection result is improved.

The invention relates to the technical field of nursing materials, and discloses eye washing liquid for relieving eye fatigue and a preparation method thereof.The eye washing liquid is prepared from trehalose, taurine, sodium gualenate, sodium hyaluronate, ergothioneine, vitamin B12, vitamin B6, xanthophyll, mint, a humectant, a bacteriostatic agent, a chelating agent, a pH regulator and deionized water. Through the synergistic effect of the first synergistic composition and the second synergistic composition, retina cell injury induced by blue light can be effectively repaired, the repairing effect is superior to that of simple addition of a single component, blue light oxidative injury is repaired through a multi-target synergistic mechanism, a three-layer structure of a tear film lipid layer, a water layer and a mucoprotein layer can be reconstructed, and the repairing effect is good. According to the present invention, the tearable film stability is significantly improved, the excellent protection and repair effect is provided, the compatibility of the components is good, the product stability is high, and the multiple effects of ocular surface cleaning, asthenopia relieving, conjunctival congestion reducing and blue light oxidation damage preventing are provided.

The application provides a composition for promoting growth of Akkermansia and application thereof, and the composition comprises milk fat globule membrane, colostrum basic protein and lacto-N-neotetraose, wherein the concentration ratio of the milk fat globule membrane, the colostrum basic protein and the lacto-N-neotetraose in the composition is (0.1-2):(0.025-0.3):(0.2-0.8). The composition can fully meet the nutritional requirements of Akkermansia bacteria, especially mucinophilic Akkermansia bacteria, can effectively promote the growth of Akkermansia bacteria, can be used for culturing Akkermansia bacteria in vitro, and can promote the growth of mucinophilic Akkermansia bacteria in the human intestinal tract, increase the potential probiotic Akkermansia bacteria in the intestinal tract, and improve intestinal health.

This invention discloses a combination drug of Akkermansia and an EET homologue and its uses, relating to the field of biomedical technology. Specifically, the combination drug of this invention comprises: A1) a first active ingredient, the first active ingredient comprising Akkermansia myxophilus; and A2) a second active ingredient, the second active ingredient comprising at least one of 14,15-epoxyeicosatetrienoic acid (14,15-EET) or an isomer of 14,15-epoxyeicosatetrienoic acid, a pharmaceutically acceptable salt, an ester, or a prodrug. The combination drug of this invention exhibits excellent anti-inflammatory and anti-tumor effects in LPS-induced inflammation models and LLC subcutaneous tumor models. The synergistic index SI > 1 calculated using the Bliss independent model indicates a good synergistic effect, and it can be used for the prevention, treatment, and prognostic improvement of non-small cell lung cancer.

The invention relates to a nanoparticle for use as a drug carrier and the synthesis method of this nanoparticle. In the invention, magnesium / aluminium (Mg / AI) mucoadhesive thiolated layered double hydroxide (nLDHT) nanoparticles are thiolated with L-cysteine and / or thioglycolic acid and / or 2-iminothiolane hydrochloride and / or glutathione and / or N-acetyl cysteine and / or 3-mercaptopropionic acid and / or 6- mercaptohexanoic acid. Thus, nLDHT interacts with the mucin on the surface of the targeted mucosal tissue for a longer period of time and acts with fewer side effects in the target tissues.

The invention relates to a probiotic composition and application thereof, and belongs to the technical field of compositions. Comprising Ackerman muciniphila ATCC BAA-835 and Bifidobacterium animalis subsp. Lactis BB-12, wherein the CFU (colony forming unit) ratio of the Ackerman muciniphila ATCC BAA-835 to the Bifidobacterium animalis subsp. Lactis BB-12 is 1 The two strains have a synergistic effect, and the prepared probiotic composition can synergistically relieve the phenomena of weight loss, colon shortening, intestinal structure and intestinal barrier injury, proinflammatory factor increase, anti-inflammatory factor reduction, intestinal flora and histidine metabolism disorder and the like of dextran sodium sulfate induced mouse ulcerative colitis. Therefore, the effect of preventing and relieving the severity of the inflammatory bowel disease is achieved.

The invention belongs to the technical field of microorganisms, and particularly relates to ackermania muciniphila AKK016 and application thereof in preparation of a product for improving and / or preventing and treating cognitive impairment, and the preservation number of the ackermania muciniphila AKK016 is CGMCC No.41190. The Ackermania muciniphila AKK016 provided by the invention can promote improvement of cognitive impairment, and the result of the embodiment shows that the result of a dark avoidance experiment in an animal experiment is positive. The ackermania muciniphila AKK016 disclosed by the invention can also improve cognition by regulating neurotransmitters related to cognition in the cerebral cortex and the hippocampus, and can also regulate the content of inflammatory factors and oxidative stress markers in the cerebral cortex. Therefore, the Ackermania muciniphila AKK016 has a better application prospect in preparation of a product for improving and / or preventing and treating cognitive impairment.